Computed Tomography (CT)-Guided Biopsy Market Size Forecast: How The Industry Is Expected To Grow From 2026 To 2030
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Computed Tomography (CT)-Guided Biopsy Market Growth From $0.82 Billion In 2026 To $1.06 Billion By 2030 At A CAGR Of 6.6%
The computed tomography (CT)-guided biopsy market has experienced substantial growth in recent years. Forecasts indicate it is projected to expand from $0.77 billion in 2025 to $0.82 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. Several factors contributed to this historical expansion, including an uptick in worldwide cancer cases, greater acceptance of diagnostic imaging techniques, the development of hospital radiology facilities, a rising inclination towards less invasive medical interventions, and enhanced access to CT imaging systems.
The computed tomography (CT)-guided biopsy market size is poised for substantial growth over the next few years. It is forecast to grow to $1.06 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.6%. This projected expansion can be linked to several factors, including the increasing demand for early-stage cancer detection, a rising adoption of precision medicine-based diagnostics, the ongoing expansion of outpatient diagnostic centers, a growing aging population requiring diagnostic interventions, and continuous advancements in biopsy needle technologies and procedural safety. Major trends anticipated during this period encompass the increasing adoption of minimally invasive diagnostic procedures for early and accurate disease detection, a rising demand for image-guided precision interventions in oncology and infection diagnosis, a growing preference for outpatient and ambulatory biopsy procedures to alleviate hospital burden, the expansion of interventional radiology departments to improve access to CT-guided procedures, and an increasing focus on early cancer screening and tissue-based diagnostics in clinical workflows.
Get A Free Sample Report With In-Depth Market Insights:
Computed Tomography (CT)-Guided Biopsy Market Growth Catalysts And Demand Drivers
An increasing occurrence of cancer is projected to stimulate the expansion of the CT-guided biopsy market in the coming years. This rise in cancer cases is largely attributed to the growing elderly demographic, given that older individuals face an elevated likelihood of forming solid tumors necessitating precise and prompt diagnostic validation. CT-guided biopsy effectively addresses this requirement through its ability to facilitate accurate tissue collection from lesions that are deep within the body or structurally intricate, especially in organs like the lung, liver, pancreas, kidney, and bone, where conventional imaging frequently falls short of providing a conclusive diagnosis and guiding therapy. For example, data released in April 2024 by the International Agency for Research on Cancer, an intergovernmental body based in France and affiliated with the World Health Organization, reported around 20 million new cancer diagnoses and nearly 10 million fatalities linked to cancer worldwide in 2022. Future demographic forecasts suggest that by 2050, the yearly count of new cancer cases is anticipated to reach 35 million, marking a substantial 77% rise from the figures recorded in 2022. Consequently, the escalating incidence of cancer is a primary force propelling the growth of the CT-guided biopsy market.
Computed Tomography (CT)-Guided Biopsy Market Segment Outlook: Which Categories Are Growing Fastest?
The computed tomography (ct)-guided biopsy market covered in this report is segmented –
1) By Biopsy Technique: Core Needle Biopsy, Fine Needle Aspiration, Vacuum-Assisted, Trephine Or Bone
2) By Target Organ: Lung, Liver, Kidney, Bone, Pancreas, Other Target Organs
3) By CT Modality: Conventional CT, CT-Fluoroscopy, Cone-Beam CT, Spectral Or Dual-Energy CT
4) By Needle System: Coaxial Systems, Non-Coaxial, Semi-Automated, Fully Automated
5) By End User: Hospitals, Imaging Centers, Ambulatory Surgical Centers
Subsegments:
1) By Core Needle Biopsy: Automated Core Needle Biopsy, Image Guided Core Needle Biopsy, Coaxial Core Needle Biopsy, Single Use Core Needle Biopsy
2) By Fine Needle Aspiration: Image Guided Fine Needle Aspiration, Endoscopic Fine Needle Aspiration, Percutaneous Fine Needle Aspiration, Ultrasound Assisted Fine Needle Aspiration
3) By Vacuum-Assisted: Image Guided Vacuum-Assisted Biopsy, Stereotactic Vacuum-Assisted Biopsy, Ultrasound Guided Vacuum-Assisted Biopsy, High Volume Vacuum-Assisted Biopsy
4) By Trephine Or Bone: Bone Marrow Trephine Biopsy, Image Guided Bone Biopsy, Percutaneous Bone Biopsy, Orthopedic Bone Biopsy
Computed Tomography (CT)-Guided Biopsy Market Trends Shaping Long-Term Demand
Major companies within the CT-guided biopsy market are concentrating on developing advanced navigation technologies, such as real-time CT navigation systems, to improve procedural accuracy, lessen radiation exposure, and optimize workflow efficiency. These real-time CT navigation systems are integrated imaging and guidance platforms that leverage 3D visualization and electromagnetic tracking to assist clinicians in precisely guiding biopsy needles to target lesions, thereby reducing the necessity for repeated imaging. As an illustration, in April 2023, GE HealthCare, a US-based medical technology company, launched its CT-Navigation solution. This system provides real-time 3D CT imaging for stereotactic needle guidance across procedures like biopsies, ablations, and drainage. It incorporates electromagnetic navigation technology, which enables complex needle trajectories, allowing clinicians to avoid critical anatomical structures. Moreover, the solution decreases radiation dose and procedure time by minimizing the need for multiple control scans, while simultaneously enhancing targeting accuracy, thus improving safety and efficiency in interventional procedures.
Computed Tomography (CT)-Guided Biopsy Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the computed tomography (ct)-guided biopsy market are Samsung Electronics, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Stryker Corporation, Medtronic PLC, Boston Scientific Inc., Becton Dickinson and Company, Siemens Healthineers, Agilent Technologies Inc., GE HealthCare Technologies, Canon Inc., Zimmer Biomet Holdings Inc., Terumo Corporation, Fujifilm Corporation, Illumina Inc., Koninklijke Philips N. V., Olympus Corporation, Hologic Inc., Teleflex Incorporated, Sysmex Corporation, QIAGEN N. V., Bio-Rad Laboratories Inc., Shimadzu Corporation, Merit Medical Systems Inc., Guerbet (GBT. PA)
View The Full Computed Tomography (CT)-Guided Biopsy Market Report:
Computed Tomography (CT)-Guided Biopsy Market Geographic Distribution And Regional Opportunities
North America was the largest region in the CT-guided biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the computed tomography (CT)-guided biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
